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Abstract
Type 1 diabetes mellitus (T1DM) is a disease characterized by chronically elevated blood
glucose levels that results from the autoimmune destruction of the insulin-producing β
cells of the pancreas. While treatment options exist, they all possess serious limitations.
Insulin  gene  therapy  provides  a  promising  alternative  aimed  at  replacing  insulin
production in native non-β cells. For insulin gene therapy applications to be successful
in treating T1DM, a glucose-sensitive organ must be targeted for insulin expression, insulin
production must be responsive to ever-changing blood glucose levels,  and insulin
expression must persist long term. In addition, the amount of insulin production is critical,
as too little insulin would lead to poor glucose regulation and too much insulin would
induce hypoglycemia, a potentially life-threatening state. Together, insulin gene therapy
provides challenges that are absent with other gene therapy applications. In this chapter,
we examine the challenges  of  insulin  gene therapy and discuss  how the two key
components of insulin gene therapy—the insulin expression cassette and the delivery
vehicle—can be tailored for the successful treatment of T1DM.
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1. Introduction
Type 1 diabetes mellitus (T1DM) is an autoimmune disorder whereby the β cells of the pancreas
are destroyed. Under physiological conditions, β cells synthesize and secrete insulin in response
to changes in blood glucose levels. Insulin, in turn, acts on other cells to promote glucose uptake
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from the blood and thus lower blood glucose levels to normal. Without sufficient numbers of
functional β cells, insulin production becomes inadequate and unable to promptly restore normal
blood glucose levels. Over time, chronically elevated blood glucose levels, termed hyperglyce‐
mia, cause numerous secondary complications, ultimately leading to widespread tissue and
organ damage, as well as increased mortality. According to the National Diabetes Statistics
Report, 29.1 million people, or 9.3% of the US population, have diabetes [1], with T1DM
accounting for roughly 5% of all diagnosed cases in the adult population. The total economic
cost of diabetes is estimated to be $245 billion per year, with T1DM costing an estimated $8–
14 billion per year. Thus, diabetes poses a significant burden to our society. Unfortunately, no
cure exists for T1DM.
1.1. Current treatment options
While there is currently no cure, several therapies exist to better control blood glucose levels.
The most common form of therapy involves use of synthetic insulin, which typically requires
multiple insulin injections per day. Unfortunately, this option is cumbersome and unable to
restore perfect glucose control. As a result, exogenous insulin therapy delays the onset and
reduces the severity of secondary complications but is unable to prevent them [2]. In addition,
exogenous insulin therapy can cause hypoglycemia, a potentially life-threatening condition
characterized by dangerously low blood glucose levels. The insufficiencies of exogenous
insulin therapy arise from the fact that most insulin regimens are unable to mimic normal β
cell secretion in response to continually fluctuating blood glucose levels. In an effort to improve
upon exogenous insulin therapy and better imitate normal physiology, specialized insulin
pumps, dubbed artificial pancreata, have been developed to deliver insulin when needed by
continuously monitoring blood glucose levels [3, 4]. Artificial pancreata are able to improve
glycemic control, but the implanted glucose sensors inevitably accumulate serum proteins that
can compromise the accuracy of glucose measurements and consequently affect the precision
of insulin delivered, limiting its long-term effectiveness. Ultimately, exogenous insulin
therapies provide a suboptimal therapy for T1DM. Conversely, tighter glucose control can be
attained through whole-pancreas transplantation [5], but this therapy is severely hampered
by a shortage of donor organs and further complicated by the need for lifelong immunosup‐
pression. Transplantation of pancreatic islets was anticipated to minimize the impact of donor
shortage, as islets from one donor could be expanded ex vivo to a quantity sufficient for multiple
recipients [6], but equivalent successes like those observed with whole-pancreas transplanta‐
tion have yet to be obtained [7]. Hence, there is clearly a need for effective and broadly
applicable treatment options for T1DM.
Gene therapy-based treatment options have emerged as a promising alternative. Gene therapy
refers to any technique aimed at using genes to treat or prevent diseases, whether it be through
delivery of a functional gene to replace a defective one or through knockdown of dysfunctional
genes using gene silencing technologies. For T1DM, three primary gene therapy approaches
have been explored to prevent or treat the disease. First, researchers have attempted to prevent
the autoimmune destruction of β cells by modifying the immune system. Second, researchers
have attempted to generate surrogate β cells from native non-β cells to replace the function of
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those cells lost from autoimmune destruction. Third, researchers have taken a more
straightforward approach and simply attempted to replace the primary function of β cells—
insulin production—to treat T1DM. Not surprisingly, each of these approaches has their own
advantages and disadvantages, which we will outline in the following sections.
1.2. Prevention of autoimmune β cell destruction
The most logical therapy for T1DM would be to take preemptive measures and prevent the
development of autoimmunity that causes β cell destruction in susceptible individuals. Not
surprisingly, many researchers have pursued this strategy as a potential alternative to current
treatment options, and to do so, various genetic modifications to both β cells and immune cells
have been tested in experimental models of T1DM. First, researchers have sought to induce
immune tolerance so that β cell antigens are no longer recognized as foreign. French and
colleagues sought to induce immune tolerance by driving intrathymic expression of proinsulin
under the control of the major histocompatibility complex (MHC) class II promoter and found
that it prevented the onset of T1DM. Similarly, Tian and colleagues transduced autologous
bone marrow hematopoietic stem cells of non-obese diabetic (NOD) mice with diabetes-
resistant MHC class II I-Aβ chain molecules to examine whether this could prevent the
development of diabetes. Indeed, they found that expression of this diabetes-associated allele
prevented the development of autoreactive T cells by intrathymic deletion and protected the
mice from developing insulitis and diabetes [8]. Second, groups have aimed to modulate the
immune system through cytokine-based approaches. For example, gene transfer of transform‐
ing growth factor-β and calcitonin gene-related peptide have been shown to prevent the onset
of diabetes in NOD mice [9, 10]. Lastly, groups have attempted to modify residual β cells so
that they can resist autoimmune destruction, an event that generally occurs through apoptosis.
Liu et al. overexpressed the antiapoptotic gene, bcl2, in β cells to increase the survival of β cells
without affecting their function [11].
Although these preventative options have shown promise, they are hampered by several
limitations: (1) These strategies rely on the early detection of diabetes. This is difficult because
individuals often do not become symptomatic until they have already lost greater than 80%
of their β cells. Thus, efforts to protect the remaining β cells would still leave the patient
hyperglycemic. (2) T1DM is a multifactorial disease, making it nearly impossible to accurately
predict who from the general population will succumb to the disease [12]. Thus, early
intervention can be risky and perhaps even accelerate the progression of the disease. (3) The
immune system is highly evolved and its complexities are not well understood. Further,
innumerable functional redundancies exist that allow the immune system to compensate for
the loss of any single factor or pathway. At our current level of understanding, it seems unlikely
that selectively targeting a specific component of the immune system could prevent the
autoimmune destruction of remaining β cells. As a result, other gene therapy strategies have
been explored.
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1.3. Reprogramming non-β cells into β cells
The goal of reprogramming non-β cells into surrogate β cells is to create replacement cells that
are as similar to native β cells as possible, including the ability to not only synthesize insulin
but also store it within secretory granules and secrete it instantaneously upon elevations in
blood glucose levels. The most common way that researchers have done so is by overexpress‐
ing β cell-specific transcription factors in non-β cells. Transcription factors are DNA-binding
proteins that modulate the rate of transcription of specific genes in a cell type-specific manner.
During development, transcription factors play a critical role in executing differentiation
programs by driving the expression of cell type-specific genes, and during adulthood,
transcription factors are important for maintaining the differentiated status of somatic cells.
For β cells, the transcription factors PDX1, NeuroD1, Neurog3, Pax4, Pax6, Nkx6.1, Nkx2.2,
and MafA are among the many transcription factors ultimately responsible for directing and/
or maintaining the β cell fate.
With the aforementioned knowledge in mind, researchers have attempted to overexpress these
transcription factors in a variety of cell types with the hopes of reprogramming them into β
cells, including pancreatic exocrine cells [13, 14], keratinocytes [15], hepatic oval stem cells [16],
adipose-derived stem cells [17], and hepatocytes. Of these, hepatocytes have been most
commonly targeted due to the fact that they are closely related developmentally to β cells and
easy to target. PDX1, which regulates early pancreas morphogenesis during development and
controls glucose-dependent insulin expression in β cells, has been shown to be indispensable
for the conversion of non-β cells into β cells. For example, Ferber et al. expressed PDX1 in the
livers of diabetic mice and observed insulin expression and secretion, as well as restoration of
normoglycemia [18]. Expression of NeuroD1 has also been shown to be a potent inducer of
insulin expression in both primary duct cells and hepatocytes [19, 20]. However, ectopic
expression of Neurog3 and Nkx6.1, which are also associated with β cell development, was
unable to generate surrogate β cells. For example, despite the ability of Neurog3 to activate
the persistent expression of NeuroD1, the use of Neurog3 in β cell engineering is not sufficient
to generate surrogate β cells [21–25]. However, co-delivery of Neurog3 with PDX1 and MafA
was successful in converting pancreatic exocrine cells into surrogate β cells [25]. Similarly,
Gefen-Halevi et al. overexpressed Nkx6.1 in liver cells but found that it alone was unable to
induce insulin expression. However, when co-expressed with PDX1, it promoted reprogram‐
ming of liver cells to β cells capable of glucose-stimulated insulin secretion [26]. Together, these
studies validate the utility of transcription factor-mediated production of surrogate β cells in
animal models and underscore its potential for treatment of T1DM.
Despite these positive findings, the long-term success of reprogramming strategies will rely
on the ability of newly formed β cells to evade preexisting autoimmunity. This is particularly
relevant given the abundance and diversity of previously identified autoantigens involved in
the autoimmune destruction of native β cells [99]. It is expected that the more similar a
surrogate β cell is to a native β cell, the more likely it will be targeted by the host’s immune
system and destroyed. For instance, while Ferber et al. found that hepatic expression of PDX1
was able to correct diabetic hyperglycemia, they also found that the mice developed hepatitis
and were prone to autoimmunity against the newly formed β cells [18]. While other studies in
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NOD mice, a mouse model of autoimmune diabetes provides hope that autoimmunity could
be avoided through reprogramming strategies [27], these studies must be carried out for longer
periods of time to assess true efficacy. Ultimately, it is likely that these strategies will either
require lifelong immunosuppression or selective immunomodulation to ensure the survival
of the surrogate β cells.
1.4. Insulin gene therapy
Given the autoimmune nature of T1DM, it may actually be unfavorable to produce surrogate
cells that closely resemble native β cells. Since the primary function of β cells is to synthesize
and secrete insulin, many groups have taken a humbler approach and simply aimed to restore
insulin production in non-β cells, a field known as insulin gene therapy. Although insulin is
also an autoantigen known to result in native β cell destruction [28], the theoretical risk of
recurring autoimmunity is greatly reduced. Of course, it should be emphasized that β cells are
extremely precise in their ability to secrete insulin upon demand, so simply expressing insulin
in a non-β cell would likely not be an effective means of treating T1DM. For instance, an
individual would not want to be producing high levels of insulin at all times because this
would cause hypoglycemic episodes. Thus, to understand whether insulin gene therapy is
indeed a viable option to treat T1DM, a clear understanding of the intricacies and aptitude of
β cells must first be attained. In the following sections, we will outline what makes a β cell so
adept at controlling glycemia and cover what criteria must be met for insulin gene therapy
approaches to be successful. We will then present an overview of the field of insulin gene
therapy to treat T1DM, with an emphasis on the unique challenges not found in other gene
therapy applications. More specifically, we will go into detail about the choice of cell type to
target in vivo, as most cell types are limited in their ability to adequately sense changing blood
glucose levels. We will then discuss key features used within insulin expression cassettes to
meet the specific needs of the field, with a particular emphasis on glucose-inducible response
elements (GIREs), before discussing the advantages and disadvantages of various viral vectors
as they pertain to the field of insulin gene therapy. Lastly, we will present future directions
necessary to make insulin gene therapy a clinical reality.
2. Insulin gene therapy
2.1. Features of the β cell
In order to determine whether insulin gene therapy possesses the necessary elegance to be a
viable treatment option, it is important to understand the key features of β cells that make
them so adept at controlling glycemia and the minimum requirements that absolutely must
be met to replace their function. Native β cells possess several important features that together
allow them to precisely control blood glucose levels. Specifically, the β cell has the ability to
regulate insulin production at the transcriptional, post-transcriptional, translational, and post-
translational levels, as well as the ability to store and secrete insulin in a highly regulated
fashion in response to glucose. While no individual feature is sufficient in itself to control
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glycemia, nor specific to β cells, the combination of features makes it a remarkably competent
cell for its task.
First and most importantly, β cells have the ability to sense and quickly respond to small
changes in circulating glucose levels over a broad range of physiological concentrations (2–20
mM) through concentration-dependent entry and metabolism of glucose. They do so through
the activity of glucose transporter-2 (GLUT2) and glucokinase. GLUT2 is a transmembrane
protein that enables glucose transport across cell membranes, whereas glucokinase is an
enzyme that phosphorylates glucose to initiate its intracellular metabolism. GLUT2 and
glucokinase have been dubbed the “glucose sensors” of β cells because they enable β cells to
sense glucose over a very broad range of concentrations. They are able to do so due to their
high Km for glucose (~17 and 8 mM, respectively), which allows their activity to vary substan‐
tially based on glucose availability [29].
β cells also have the ability to secrete insulin in a precisely regulated fashion in response to
elevations in blood glucose levels. β cells do so through their capacity to (1) synthesize and
store large quantities of insulin within secretory vesicles and (2) generate secondary stimulus-
secretion coupling signals to activate nearly instantaneous insulin vesicle exocytosis. Remark‐
ably, β cells can secrete substantial quantities of insulin within a minute after exposure to
elevated glucose. This is a consequence of their metabolic capabilities; β cells possess a unique
combination of metabolic enzymes that ultimately leads to the generation of signals capable
of altering insulin secretion in response to glucose metabolism. Namely, β cells, but not other
mammalian cell types, have negligible lactate dehydrogenase activity while displaying
increased pyruvate carboxylase activity, which directs pyruvate almost entirely toward
mitochondria for subsequent metabolism via the tricarboxylic acid cycle and oxidative
phosphorylation [30]. In so doing, β cells increase their ratio of ATP/ADP and activate ATP-
sensitive K+ channels, a key stimulus leading to insulin vesicle exocytosis.
Furthermore, β cells have remarkable control of insulin biosynthesis at the transcriptional,
post-transcriptional, translational, and post-translational levels, with each level of control
being regulated by glucose availability. At the transcriptional level, increased glucose levels
lead to upregulated insulin expression through the enhanced activity of the transcription
factors, PDX1 and MafA [31, 32]. At the post-transcriptional and translational levels, β cells
have glucose-responsive mechanisms to modulate insulin mRNA stability and the rate of
translation, respectively. This glucose-dependent regulation is primarily governed by an RNA-
binding protein known as polypyrimidine tract-binding protein (PTB). Association of PTB
with a pyrimidine-rich stretch in the 3′ untranslated region (UTR) of the preproinsulin mRNA
has been shown to be responsible for glucose-dependent changes in its stability and rate of
translation [33, 34]. In fact, the half-life of preproinsulin mRNA has been shown to increase
nearly 3-fold as a result of PTB association [35, 36]. At the post-translational level, β cells
possess specific enzymes that allow them to process proinsulin—a precursor form—into fully
active insulin. Proinsulin conversion involves removal of two basic pairs of amino acids—the
C-peptide—and is mediated by the β cell endoproteases, PC1/3 and PC2, and the exopeptidase,
carboxypeptidase-H [37, 38]. Altogether, β cells have a variety of glucose-dependent mecha‐
nisms to control insulin output.
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β cells further refine insulin biosynthesis and secretion in response to other circulating
metabolites. First, the gut produces the peptide hormones, glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1, which bind specific receptors found predom‐
inantly on β cells to bolster insulin production [39]. Second, specific amino acids and free fatty
acids can serve as insulin secretagogues. While some amino acids and free fatty acids can
actively promote insulin secretion, most of them simply have a role in amplifying the stimu‐
latory effects of glucose [40]. Third, metabolic stress can induce neuronal signals that influence
insulin output [41]. Together, these inputs regulate insulin production and secretion from β
cells to more precisely maintain glucose levels within a normal range.
2.2. Requirements of insulin gene therapy
Combining all the remarkable features of the β cell, the end product is a cell with impressive
glucose sensitivity, the ability to control insulin biosynthesis at several levels in a glucose-
dependent fashion, and the ability to store, process, and secrete insulin almost instantaneously
in response to glucose. The β cell is truly impressive. With this knowledge in mind, it would
be easy to argue that insulin gene therapy lacks the sophistication necessary to adequately
treat T1DM, especially given its relative simplicity. However, it is important to keep in mind
that the most commonly used treatment for T1DM currently involves repeated injections of
synthetic insulin. While this treatment option holds very little sophistication or biomimicry, it
has still proven effective enough to remain a viable option since it was first employed as a
medication in 1922. With that being said, any treatment that could provide better glycemic
control while averting the cumbersome nature of synthetic insulin therapy would be a
noteworthy improvement. So, beyond the ability to produce insulin alone (a feat that could
likely be achieved in any cell type using a strong constitutive promoter), what other features
of β cells are absolutely critical for the success of insulin gene therapy applications?
Given that glucose is the primary stimulus leading to the production of insulin and subsequent
clearance of itself, the impressive glucose sensitivity conferred by GLUT2 and glucokinase is
a necessary feature that must be present in an insulin-producing surrogate β cell. Without these
proteins, a surrogate β cell would not be able to precisely sense glucose concentration and
control insulin output over a broad range of circulating glucose concentrations. In addition to
glucose sensitivity, it is also important that the insulin-producing surrogate cell has the ability
to respond to changing blood glucose levels by modulating insulin output. In so doing, insulin
output could be adjusted in a physiologically relevant manner to better control glycemia. It is
likewise important for an insulin-producing cell to have the ability to process proinsulin into
insulin, given that proinsulin has less than 10% of the biological activity of fully processed
insulin [42]. Lastly, it would be ideal for an insulin-producing cell to have the ability to package,
store, and secrete insulin almost instantaneously in response to elevated blood glucose levels.
However, it is debatable whether this last feature is indeed critical to the success of insulin
gene therapy. Diabetes is such a devastating disease because of the secondary complications
that arise as a consequence of sustained hyperglycemia, not repeated episodes of transient
hyperglycemia. Thus, as long as the insulin-producing surrogate cell has the ability to produce
sufficient quantities of insulin within a reasonable time frame in a glucose-responsive fashion,
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the difference between near instantaneous insulin secretion or secretion with a few minutes'
delay may be less critical. The quantity of insulin secreted must simply be large enough to
correct hyperglycemia, but not too large as to cause hypoglycemia.
Thus, a long-lasting treatment for T1DM using insulin gene therapy could be achieved, but
several criteria must be considered. First, the appropriate cells must be targeted for insulin
production. At a minimum, these cells would need to express the glucose sensors, GLUT2 and
glucokinase. Second, insulin transgene expression must be responsive to fluctuating blood
glucose levels, being upregulated during hyperglycemia and downregulated during euglyce‐
mia. There are a variety of mechanisms available to endow an insulin-producing surrogate β
cell with this ability. Third, there must be some mechanism in place for the target cell to process
proinsulin into mature insulin. Lastly, an appropriate gene correction tool must be utilized to
safely and effectively drive long-term insulin expression.
While meeting these criteria provides several challenges, treating T1DM through insulin gene
therapy presents additional challenges not associated with other gene therapy strategies. First,
insulin has a relatively short half-life compared to many other proteins being used for gene
therapy applications. For instance, the circulating half-life of coagulation factor IX, which is
deficient in hemophilia B patients, is estimated to be around 18–25 hours [43], whereas the
circulating half-life of insulin has been estimated to be around 4–6 minutes. To compensate for
the short circulating half-life of insulin, it is necessary to produce large amounts of insulin
either by developing a highly effective gene expression system or by transducing a larger
number of cells than other gene therapy applications. This makes the choice of gene delivery
system a critical one, as the delivery vehicle must be produced in great abundance and
transduce cells efficiently in vivo. Second, basal insulin production must be kept low during
fasting periods and upregulated only when blood glucose levels become elevated. Other gene
therapy applications need only to deliver the therapeutic protein of interest constitutively at
low levels to correct the clinical manifestation, owing to greater protein stability and the
particular function of the protein. If insulin was expressed constitutively at low levels to satisfy
basal metabolic activity, there would be long periods of postprandial hyperglycemia, and if
the level of constitutive insulin production was increased to effectively control postprandial
glucose levels, there would be a very high possibility of hypoglycemia during fasting periods.
Thus, insulin expression cannot be driven by a strong constitutive promoter; it instead must
be responsive to fluctuating blood glucose levels. This makes the design of the insulin
expression cassette extremely important. It also creates a much narrower therapeutic window
for dosing than other gene therapy applications. In the following sections, we will discuss these
factors in depth.
2.3. Target cells for insulin gene therapy
At a minimum, the target cells chosen for insulin gene therapy would need to express GLUT2
and glucokinase and have innate mechanisms for glucose-responsiveness, thus giving them
the ability to sense and respond to continually fluctuating blood glucose levels. Without them,
insulin secretion from surrogate β cells would be far less precise. Besides β cells, the only cells
that express both GLUT2 and glucokinase are hepatocytes and cells of the hypothalamus and
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small intestine. Thus, these cells serve as a nice starting point for targeting of insulin transgene
expression. It should be noted, however, that a variety of other cells have been targeted for
insulin expression, including skeletal myocytes, fibroblasts, and mesenchymal stem cells. An
interesting example is the targeting of skeletal myocytes. Skeletal myocytes do not express
GLUT2 or glucokinase. Instead, they express GLUT4 and hexokinase, which each have a higher
affinity (i.e. lower Km) for glucose. To endow skeletal myocytes with enhanced glucose
sensitivity, Callejas et al. co-expressed insulin with glucokinase. Whereas insulin alone was
insufficient to adequately treat T1DM in dogs using skeletal myocytes as surrogate β cells, co-
expression of glucokinase with insulin was able to normalize fasting hyperglycemia and
accelerate glucose disposal after oral challenge [44]. These findings emphasize the importance
of glucose sensitivity in treatment of T1DM.
Intestinal K cells provide a particularly promising cell type for insulin gene therapy applica‐
tions because they not only express GLUT2 and glucokinase, but they also possess the
proinsulin processing enzymes and have the machinery for regulated insulin secretion.
Cheung and colleagues exploited these unique advantages to generate insulin-producing
surrogate β cells from K cells. To do so, they generated transgenic mice expressing human
insulin under control of the GIP promoter, a K cell-specific promoter believed to be regulated
by glucose [45]. They found that the GIP promoter was able to target insulin expression to K
cells specifically, and the transgenic expression of insulin was effective at promoting normal
fasting glucose levels and efficient glucose clearance in response to an oral glucose challenge
for up to three months after mice were rendered diabetic with streptozotocin (STZ). However,
while their findings hold promise, the translation of this strategy to the clinic will rely on their
ability to address the following concerns: (1) The gut is one of the primary hubs for the immune
system, and given that insulin itself is an autoantigen responsible for native β cell destruction
[46], intestinal K cells may be particularly susceptible to recurring autoimmune attack; long-
term protection from autoimmunity must be demonstrated. (2) More importantly, the GIP
promoter is not only regulated by glucose intake but also by other sources—most notably fats.
Thus, patients receiving this treatment would, at the very least, need to maintain a very strict
diet to avoid potentially fatal consequences, like hypoglycemia. Further, another study found
that glucose alone does not even regulate insulin secretion when controlled by the GIP
promoter [47]. Regulation of the GIP promoter must be more thoroughly examined before
moving toward human clinical trials.
The most commonly chosen target cells of insulin gene therapy applications, and the one we
have chosen, are hepatocytes. Although hepatocytes do not have the machinery to store insulin
within secretory vesicles and secrete it in a regulated fashion, they express GLUT2 and
glucokinase and possess a robust capacity to synthesize and secrete proteins constitutively. In
addition, hepatocytes are attractive targets for insulin expression because they (1) are closely
related to β cells developmentally, (2) play a very important role in glucose homeostasis, and
(3) are relatively easy to target. As a result, it has been the most commonly targeted organ for
in vivo production of insulin-producing surrogate β cells and will be the focus for the remainder
of this chapter.
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2.4. Expression cassette design
After choosing an appropriate cell type for insulin production, there are several considerations
that must be taken into account when designing the insulin expression cassette. Perhaps the
first decision that must be made is which promoter to use to drive insulin expression. One of
the most commonly used promoters within the field of gene therapy is the cytomegalovirus
(CMV) promoter. The CMV promoter is a mammalian promoter from the human cytomega‐
lovirus that drives strong, constitutive transgene expression. While the CMV promoter has
been used quite frequently to drive insulin expression for treatment of T1DM, there is one
fundamental reason why these studies could never be translated to the clinic: Insulin expres‐
sion must be responsive to glucose, being upregulated when blood glucose levels rise and
downregulated to low levels during fasting periods. The CMV promoter would drive consis‐
tent, high level expression of insulin even during fasting periods, which would ultimately
cause blood glucose levels to fall dangerously low. Furthermore, even if regulatory elements
were added to the expression cassette to endow glucose-responsiveness to insulin expression,
the CMV promoter is so strong that it would override these elements. Thus, a weaker promoter
must be used to maintain low levels of insulin production during fasting periods if insulin
gene therapy is to be successful in treating T1DM.
Weaker tissue-specific promoters have been employed for hepatic insulin gene therapy
applications to not only reduce the potential for hypoglycemia but also to improve targeting
to the tissue of choice. For instance, several groups have used liver-specific promoters that
activate insulin transgene expression in hepatocytes but remain inactive in other cell types.
Interestingly, some liver-specific promoters are inherently glucose-responsive, making them
a great choice for insulin gene therapy applications. For instance, Chen et al. used the glucose-6-
phosphatase (G6Pase) promoter to drive insulin expression and found that elevated glucose
concentrations enhanced promoter activity [48]. They also found that insulin strongly inhibited
G6Pase promoter activity under low glucose conditions, creating a system with feedback
inhibition [49]. The group then delivered the insulin gene to the liver of STZ-induced diabetic
rats under the control of the G6Pase promoter and found that ad libitum hyperglycemia was
significantly reduced, glucose utilization was accelerated after glucose challenge, and fasting
glucose levels were within a normal range without hypoglycemia. Similarly, Burkhardt et al.
used the liver-specific GLUT2 promoter to drive insulin gene expression in a glucose-inducible
but insulin-repressive fashion and found an improvement in diabetic hyperglycemia [50].
However, it is worth noting that the activity of the wild-type insulin promoter used by native
β cells is actually enhanced by insulin, creating a feed-forward system to amplify insulin
expression.
To generate a more physiologically mimetic system driving insulin expression, Hsu and
coworkers used the rat insulin-1 promoter, creating a system that is activated by both glucose
and insulin, similar to native β cells [51]. In so doing, they were successful at driving insulin
secretion from Huh7 hepatoma cells in vitro in response to glucose. They were also able to
augment insulin expression in vivo in response to glucose and theophylline—a pharmacolog‐
ical activator of cAMP—and ameliorate hyperglycemia in STZ-induced diabetic mice. How‐
ever, they did not test whether insulin activated transgene expression using this promoter,
Modern Tools for Genetic Engineering142
and it is unclear how this promoter was active in hepatocytes, which do not ordinarily express
the β cell-specific transcription factors necessary to upregulate insulin expression. Regardless,
hepatocytes do not possess enough of the β cell-specific regulatory mechanisms to safely
express insulin in a feed-forward manner with respect to insulin. Thus, for the sake of hepatic
insulin gene therapy, it would be simpler to create a system that was unresponsive to insulin
altogether.
Even if a liver-specific promoter does not possess glucose responsiveness, it can be endowed
with sensitivity to glucose through incorporation of GIREs. GIREs are glucose-responsive
DNA sequences found in the promoter region of several genes encoding lipogenic enzymes,
like L-pyruvate kinase (L-PK), S14, fatty acid synthase, and acetyl-CoA carboxylase [52]. GIREs
are composed of two 6-bp motifs known as E boxes, with a consensus sequence of
CACGTGnnnnnCACGTG (Figure 1). E boxes are generally recognized by transcription factors
harboring basic helix-loop-helix/leucine zipper DNA-binding domains [53]. A specific
transcription factor, dubbed carbohydrate response element-binding protein (ChREBP), has
been found in great abundance in the liver, as well as the small intestine and adipose tissue,
the most active sites of de novo lipogenesis [54].
Figure 1. Glucose-inducible response elements (GIREs) and their transcriptional activators.
Incorporation of GIREs enables glucose-responsive control of gene transcription. GIREs are
composed of two 6-bp motifs with a consensus sequence of CACGTG separated by 5 bp. A
tetramer of ChREBP-Mlx binds each GIRE to amplify gene transcription in response to elevated
glucose levels. GIREs have been identified in liver-specific genes like L-pyruvate kinase (L-
PK), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS).
Thule and colleagues leveraged GIREs to endow glucose-responsiveness to the liver-specific
insulin-like growth factor binding protein-1 (IGFBP1) promoter. The IGFBP1 promoter is
repressed by insulin, creating a feedback inhibition loop on insulin expression, but it is not
inherently influenced by changes in glucose concentrations. To generate glucose-responsive
insulin expression, they incorporated GIREs from the L-PK gene directly upstream of the
IGFBP1 promoter and found that, depending on the number of GIREs incorporated, a 1.6- to
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6.4-fold increase in promoter activity could be produced in response to elevated glucose
concentrations in primary hepatocytes in vitro [55]. In addition, Thule and Liu used a recombi‐
nant adenovirus to deliver their glucose-responsive, insulin-repressive insulin construct into
STZ-induced diabetic rats and found that it was able to produce near-normal glycemia and
weight gain without inducing lethal hypoglycemia [56].
In our lab, we used the liver-specific albumin promoter—which is neither glucose- nor insulin-
responsive—and inserted the GIREs from the S14 gene upstream of the albumin promoter to
create a system that is unresponsive to insulin but activated by elevated glucose levels
(Figure 2) [57]. To test the effect that the S14 GIREs have on glucose-responsive insulin output
from the albumin promoter, we first generated insulin expression cassettes containing one to
five GIREs. Interestingly, we found that the degree of glucose-induction on insulin output
increased as the number of GIREs was increased up to three, after which there was only a
marginal enhancement in insulin output. We observed a 9-fold increase in insulin output from
primary hepatocytes between low and high glucose conditions when three GIREs were
incorporated upstream of the albumin promoter (Figure 3). When we delivered this insulin
expression cassette into the livers of STZ-induced diabetic rats through direct injection, we
found that fasting blood glucose levels were reduced to normal, blood glucose levels of diabetic
rats fed ad libitum were significantly reduced, and glucose clearance was significantly accel‐
erated during an intraperitoneal glucose tolerance test. However, these effects only lasted for
roughly a month, owing to the use of adenoviral vectors to deliver our insulin expression
cassette.
Figure 2. Elements of the insulin expression cassette—TA1.
TA1 is a 2.1-kb insulin expression cassette containing elements that drive insulin expression
in both a liver-specific and glucose-responsive fashion. The albumin promoter is largely
Modern Tools for Genetic Engineering144
responsible for restricting insulin expression to hepatocytes, while the α-fetoprotein transcrip‐
tional enhancer, vascular endothelial growth factor (VEGF) translational enhancer, and
albumin 3′-UTR also promote liver specificity. Glucose responsiveness is primarily driven by
three copies of GIREs, although the albumin 3′-UTR also promotes glucose-responsive insulin
biosynthesis.
Figure 3. Glucose induction of insulin expression and the effect of hepatocyte-specific enhancer elements on overall
insulin output.
The insulin expression cassettes, TA0 and TA1, differ in the presence of α-fetoprotein tran‐
scriptional enhancer and the albumin 3′-UTR. Inclusion of these elements greatly increases
overall insulin output, while both constructs display similar glucose responsiveness.
To improve our insulin expression cassette, we investigated whether inclusion of various liver-
specific enhancer elements could further enhance insulin production. Specifically, we incor‐
porated a transcriptional enhancer from the human α-fetoprotein gene, an intron from the
human growth hormone gene previously shown to improve mRNA processing efficiency, a
translational enhancer from the vascular endothelial growth factor (VEGF) gene that functions
as an internal ribosomal entry site, and the 3′-UTR from the human albumin gene that also
contains an intron to improve mRNA processing (Figure 3). The ability of each element to
enhance glucose-inducible insulin expression was first examined by transducing primary rat
hepatocytes in vitro using an adenovirus. After testing different constructs containing a variety
of different combinations of these elements, we ultimately found that insulin expression
cassettes incorporating the α-fetoprotein transcriptional enhancer, VEGF translational
enhancer, and albumin 3′-UTR led to increased insulin production ex vivo. Specifically, the
VEGF translational enhancer led to a 4- to 6-fold increase in insulin output alone at both low
and high glucose concentrations. Incorporation of the transcriptional enhancer and 3′-UTR led
to another 5- to 8-fold increase in insulin output (Figure 3). Together, these modifications to
the insulin expression cassette resulted in a 20- to 50-fold increase in insulin output in vitro
compared to the original constructs, thus allowing us to more efficiently drive insulin expres‐
sion, a particularly important factor when less efficient delivery vehicles must be used for gene
therapy.
We confirmed the utility of this improved insulin construct in vivo by delivering our insulin
expression cassette in the form of minicircle DNA, which can be readily produced in large
quantities. Upon intravenous injection of this minicircle DNA into STZ-induced diabetic rats,
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we observed a DNA dose-dependent correction in hyperglycemia in both fasted rats and rats
fed ad libitum. In addition, we observed a full restoration in the rate of weight gain in STZ-
induced diabetic rats comparable to that of healthy, non-diabetic rats, and intraperitoneal
glucose tolerance tests demonstrated glucose-inducible increases in insulin production
capable of correcting hyperglycemia within 45 minutes. A single injection of minicircle DNA
led to normalization of serum levels of albumin, triglycerides, cholesterol, aspartate transa‐
minase, alanine aminotransferase, and alkaline phosphatase, thus demonstrating restoration
of healthy liver function. Further, there were no signs of hepatic inflammation, underscoring
the safety of hepatic insulin gene therapy. Together, we were able to create a treatment for
T1DM possessing glucose-responsive insulin production (due to the natural expression of
GLUT2 and glucokinase from hepatocytes, and the presence of GIREs in the insulin expression
cassette) that is capable of fully correcting diabetic hyperglycemia.
Another novel feature of our insulin expression cassette is the presence of the albumin 3′-UTR.
As mentioned previously, the albumin 3′-UTR contains an intron that improves mRNA
processing. However, in addition to that, it also contains two pyrimidine-rich stretches known
to bind PTB [58]. PTB is a ubiquitously expressed mRNA binding protein that serves as a
common mediator of mRNA stability. As mentioned previously, PTB binding sequences are
also found in the 3′-UTR of the preproinsulin gene. This is a particularly important feature for
hepatic insulin gene therapy applications, as the half-life of preproinsulin mRNA has been
reported to be less than 6 hours in hepatocytes. That is much less than the 29–77 hours found
in β cells. Perhaps even more importantly, the presence of PTB binding sites would also confer
glucose-responsive control of preproinsulin mRNA translation in hepatocytes [34]. Thus, the
presence of the albumin 3′-UTR endows hepatocyte-derived surrogate β cells with improved
mRNA processing and stability, as well as glucose-responsive control of translation.
One final consideration when designing an expression cassette for insulin gene therapy is the
preproinsulin sequence used. A mature insulin molecule is composed of two polypeptide
chains—the A and B chains—linked together by two disulfide bonds. However, the insulin
gene produces a single preproinsulin polypeptide that contains two basic pairs of amino acids
separating the A and B chains, known as the C-peptide, as well as a 24-residue signal peptide.
The signal peptide is removed as preproinsulin is translocated into the rough endoplasmic
reticulum, forming proinsulin. Proinsulin undergoes further maturation within secretory
granules through the action of prohormone convertases PC1/3 and PC2, as well as carboxy‐
peptidase-H. These enzymes are co-packaged with proinsulin in secretory granules and
together act to remove C-peptide and produce mature insulin. However, prohormone
convertases PC1/3 and PC2 are only found in β cells and other cells with the regulated secretory
pathway, like pituitary cells and intestinal K cells. Thus, for insulin gene therapy applications
to be successful, it is important to maintain proinsulin processing, even if researchers choose
to target cell types that do not have the regulated secretory pathway, like hepatocytes. In these
instances, modifications can be made to the preproinsulin sequence to bypass the necessity of
PC1/3 and PC2. The most commonly used modification is incorporation of furin cleavage sites
[59, 60]. Furin is a ubiquitously expressed endoprotease that can efficiently cleave proteins at
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paired basic amino acid sites. Through incorporation of furin cleavage sites, any cell of the
body can produce fully functional insulin.
Further modifications can be made to the preproinsulin sequence to enhance bioactivity or
production for insulin gene therapy applications. First, the preproinsulin sequence can be
mutated to alter the stability of the resulting insulin molecules. The most prevalently used
mutation is the B10 mutation—a naturally occurring mutation where the histidine residue at
position 10 on the B chain is replaced by aspartic acid [59, 61]. This mutation results in enhanced
stability and the accumulation of 10- to 100-fold more mature insulin than wild-type insulin.
Other mutations have been found to result in highly potent insulin analogues, including
HisA8, ArgA8, and GluB10 [61].
Another way the preproinsulin sequence can be modified is through codon optimization. A
codon is a series of three nucleotides that encode a specific amino acid. There are 64 different
codons but only 20 different amino acids, which means that many amino acids are encoded
by multiple codons. It is generally acknowledged that different organisms have codon
preferences as a result of the composition of their respective tRNA pool. In other words, specific
codons are preferred by specific organisms because they have that specific tRNA in greater
abundance. It is thought that cDNA sequences with optimized codons will achieve faster rates
of translation and accuracy, thus improving translational efficiency and production of the
transgene product. For gene therapy applications, this has been shown to improve the potency
of treatment. For instance, Cantore et al. observed a 2- to 3-fold increase in potency of their
factor IX treatment for hemophilia B in dogs upon codon optimization [62]. Codon-optimized
versions of human insulin have also been shown to achieve better glycemic control in diabetic
dogs due to increases in insulin production [44].
In summary, there is some flexibility in the design of the expression cassette for insulin gene
therapy applications; the relatively small size of the preproinsulin gene is advantageous for
the design of an expression cassette and its subsequent delivery to target cells. Regulatory
elements capable of improving cell type specificity, overall insulin output, and glucose
responsiveness can be employed to yield insulin expression with greater precision. In addition,
the preproinsulin sequence itself can be modified to improve production and functionality.
Once a sufficient level of control has been attained over insulin expression, it then becomes a
matter of delivering the expression cassette to target cells in a safe and efficient manner.
2.5. Delivery vehicles for insulin gene therapy
When choosing a delivery vehicle for insulin gene therapy applications, two important
considerations must be taken into account. First, the delivery vehicle must be able to promote
long-term insulin expression. This is important because an antibody response from the initial
treatment will reduce the efficacy of subsequent treatments. Thus, repeated administration of
most delivery vehicles is largely ineffective, especially if it occurs more than two weeks after
the initial treatment. Second, it must be possible to affordably and reliably produce the gene
delivery vehicle in the large quantities needed for gene therapy. This is particularly important
in the field of insulin gene therapy because the insulin molecule has a relatively short circu‐
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lating half-life, estimated at around 4–6 minutes [63]. As a result, a greater number of cells
must be targeted for insulin expression than other gene therapy applications.
Many gene delivery vehicles exist and can be broadly grouped into two categories: viral and
non-viral. Non-viral methods have the advantages of being safer and inducing less of an
immune response. However, non-viral methods typically only drive transgene expression
transiently, as most are incapable of supporting chromosomal integration. In addition, they
tend to deliver genes inefficiently in vivo. Regardless, we explored the potential of delivering
the insulin gene in the form of minicircle DNA to validate the in vivo efficacy of our expression
cassette. We chose to use minicircle DNA because they can be produced in large quantities
and contain no bacterial or viral elements, improving their likelihood of evading the immune
system. We found that delivering our insulin expression cassette as a minicircle was able to
correct diabetic hyperglycemia in a dose-dependent fashion in STZ-induced diabetic rats
(Figure 4). While the effects of this treatment only persisted for about a month, the reduced
immunogenicity of minicircle DNA allowed for repeated administration, although the second
injection was not nearly as effective as the first (Figure 5) [64].
Figure 4. Dose-dependent effect of insulin minicircle DNA treatment on hyperglycemia in rats.
STZ-induced diabetic rats were intravenously injected with the indicated dose of TA1m
minicircle DNA and measured for both fasting (A) and ad libitum (B) blood glucose levels.
There was a dose-dependent correction of diabetic hyperglycemia that persisted for at least 10
days.
Modern Tools for Genetic Engineering148
Figure 5. Effect of repeated administration of insulin minicircle DNA on fasting hyperglycemia in diabetic rats.
STZ-induced diabetic rats were intravenously injected with 0.8 μg/gm body weight of TA1m
via tail vein, and blood glucose measurements were made after a 4-hour fast. TA1m was able
to correct diabetic hyperglycemia for nearly a month before the effects began to diminish. A
second TA1m injection (0.8 μg/gm body weight) was made on the 26th day and was able to
re-correct fasting blood glucose levels, thus demonstrating that a substantial humoral response
had not been mounted against the minicircle DNA.
We have also explored the use of viral delivery vehicles, as viruses are highly evolved and
proficient at delivering genetic information into target cells. Of course, viral vectors will
inevitably elicit an immune response, with some viruses invoking a greater immune response
than others. Several viral vectors have been used for insulin gene therapy, with each possessing
their own unique features. Refer to Table 1 for an overview of the features inherent to various
viral vectors.
Viral vector Packaging
capacity
Length of
expression
Relative viral
titer
Transduction
efficiency
Infect both
dividing and
non-dividing
cells
Immunogenicity
Adenovirus 7.5 kb Transient +++ +++ Yes High
Adeno-associated
virus
4.5 kb Transient and
Stable
++ ++ Yes Low
Oncoretrovirus 8 kb Stable + + No Moderate
Lentivirus 8 kb Stable + ++ Yes Low
Table 1. Features of various viral vectors for gene therapy applications.
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Adenovirus, adeno-associated virus, oncoretrovirus, and lentivirus are the most commonly
used delivery vehicles for gene therapy applications. Each viral vector possesses their own
unique features that affects their suitably for insulin gene therapy applications.
Adenoviruses were among the first viral vectors used in the field of insulin gene therapy due
to their ability to be produced in very high titers and transduce non-dividing cells with high
efficiency. These features allow researchers to transduce a large number of cells in vivo and
overcome the lack of insulin protein stability. However, adenoviral vectors are unable to
integrate their genetic cargo into the host's genome and thus provide only transient gene
expression [65, 66]. As a proof-of-principle, we initially used adenoviral vectors to establish
the efficacy of our insulin expression cassette in vivo. Indeed, we were successful at correcting
fasting blood glucose levels and improving ad libitum glucose levels in diabetic rats (Fig‐
ure 6). As expected, however, the observed reduction in blood glucose levels only persisted
for about a month. This observation is in agreement with other studies using adenoviral vectors
to deliver the insulin gene into diabetic animals, which likewise noted an improvement of
hyperglycemia for only a month [67]. Unfortunately, unlike minicircle DNA, a humoral
response is elicited by the first treatment, precluding repeated administration of adenovirus-
based treatments. Thus, while adenoviral vectors are extremely efficient gene delivery tools,
they are not well suited as a long-term therapeutic tool for treatment of T1DM, at least in their
initial form.
Figure 6. Effect of TA1 on hyperglycemia in diabetic rats when delivered via adenovirus.
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STZ-induced diabetic rats were injected with 2 × 1010 adenoviral pfu/rat, and both fasting (A)
and ad libitum (B) blood glucose measurements were made. Treatment with adenoviral vectors
carrying the TA1 insulin expression cassette were able to fully correct diabetic hyperglycemia
after an overnight fast and partially correct ad libitum blood glucose levels for around one
month.
More recently, researchers have generated a newer version of “gutted” adenoviral vector that
has been stripped of all viral coding sequences, greatly reducing their immunogenicity [68,
69]. This is an important advancement in the field of gene therapy because adenoviral vectors
have proven so immunogenic in past human clinical trials that their administration led to the
death of a patient in 1999, temporarily halting progress in the field of gene therapy [70, 71].
Immunogenicity is undoubtedly a very large concern with adenoviral vectors, so any im‐
provement is useful. However, it seems unlikely that immunogenicity will ever be completely
eliminated from adenoviral vectors, or any viral vector for that matter. Further advancements
have now made it possible to improve upon the innate capabilities of adenoviral vectors by
adding the potential to integrate their genetic cargo into a host's genome and drive long-term
transgene expression. The advancement was a result of the merging of two technologies, where
chromosomal integration is mediated by the Sleeping Beauty (SB) transposon system and
efficient gene delivery accomplished by the gutted adenoviral vectors. DNA transposons
translocate from one DNA site to another through a simple cutting-and-pasting process,
enabling the integration of defined DNA sequences into mammalian genomes [72]. To achieve
stable transgene expression using this system, two separate adenoviral vectors must be
administered and co-transduce a single cell. The first vector represents the transposon donor
vector, which contains a transposon encoding the transgene of interest. The second vector
encodes the SB transposase, which mediates relocation. This system has been used successfully
to enable persistent phenotypic correction of hemophilia B in dogs [72] and holds great
potential for the treatment of other diseases that require persistent gene expression.
To combat issues related to immunogenicity and short-term expression, other groups have
employed adeno-associated virus (AAVs). AAVs are able to transduce both dividing and non-
dividing cells. In dividing cells, AAVs are able to integrate transgenes into the host's genome
at a specific site on chromosome 19 [73]. Within non-dividing cells, the AAV genetic cargo
remains largely episomal, as the chromatin is less accessible. AAVs are less immunogenic than
adenoviral vectors and are reported to cause relatively long-term transgene expression in non-
dividing cells. The primary disadvantage of using AAVs is that their packaging capacity is less
than 5 kb, limiting the use of larger expression cassettes with greater complexity for regulated
expression. However, the preproinsulin gene is quite small, so even when the gene is accom‐
panied with multiple regulatory elements in a complex expression cassette, the maximum size
limitation is unlikely to become an issue for insulin gene therapy applications. Indeed, AAVs
have been used to successfully drive insulin expression within non-β cells. Park et al. used
AAV to deliver insulin under control of the CMV promoter into STZ-induced diabetic rats and
found improved glucose tolerance (at 2 g/kg) comparable to that of non-diabetic control rats
[74]. Additionally, they observed a less pronounced immune response using AAV when
compared to the same treatment using adenoviral vectors.
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Retroviral vectors are another widely used gene delivery vehicle, owing to their ability to
integrate their genetic cargo into a host's genome and attain sustained gene expression.
However, retroviral vectors are greatly limited by their inability to integrate their cargo into
the chromosomes of non-dividing cells, a problem that severely hinders their utility in insulin
gene therapy applications. In cases where retroviral vectors have been used to deliver insulin,
hepatocyte proliferation must first be stimulated [75]. This, of course, greatly limits the
translation of retroviral vectors for treatment of T1DM. Retroviral vectors have also been
shown to have a preference to integrate their genetic cargo in close proximity to the transcrip‐
tional regulatory sequences of proto-oncogenes, as observed in 1999 following the treatment
of nine severe-combined immunodeficiency patients [76]. Insertional mutagenesis led to the
development of leukemia in four of the nine patients, ultimately halting the field of clinical
gene therapy temporarily. All in all, retroviral vectors do not possess favorable features for
insulin gene therapy applications.
Lentiviral vectors are a type of retrovirus that provide two key advantages over other retro‐
viruses: (1) they are able to integrate their genetic cargo into the genome of both dividing and
non-dividing cells and (2) have less preference to integrate near regulatory sequences of proto-
oncogenes, reducing the risk of insertional mutagenesis [77, 78]. Their ability to transduce non-
dividing cells is critical for gene therapy strategies, as most cells of the body are either non-
dividing or slowly dividing. An additional advantage of lentiviral vectors is that they do not
elicit a strong immune response. Unfortunately, lentiviral vectors possess two major pitfalls
limiting their widespread translation to human clinical trials: (1) Lentiviral vectors are difficult
to produce in high titer [79] and (2) the efficiency of lentiviral transduction in vivo is signifi‐
cantly lower than other vectors, especially adenoviral vectors. Given the relative instability of
insulin, the need to transduce a larger number of cells than other gene therapy applications,
and the fact that—unlike other diseases—a partial correction of hyperglycemia is not sufficient
to adequately treat T1DM, these pitfalls pose some limitations to the use of lentiviral vectors
for insulin gene therapy applications. Nonetheless, lentiviral vectors offer long-term transgene
expression with reduced immunogenicity and an improved biosafety profile and are thus a
viable candidate as a therapeutic tool for treatment of T1DM.
To combat issues related to lentivirus infectivity, researchers have modified lentiviral vectors
to improve their in vivo efficacy. For example, Naldini et al. has previously shown that inclusion
of viral protein R—a viral protein present in native HIV-1 particles—within synthetic lentiviral
particles is critical for hepatocyte transduction [80]. Conversely, Schaffer et al. has generated
vesicular stromatitis virus envelope proteins that show improved serum resistance [81], which
could improve lentiviral efficacy in vivo. A combination of modifications will hopefully yield
a more potent lentiviral particle in vivo. Interestingly, Ren and colleagues used lentiviral
vectors to deliver insulin to the livers of STZ-induced diabetic rats [82] and NOD mice [83] and
observed long-term correction of diabetic hyperglycemia with no evidence of impaired liver
function, intrahepatic inflammation, or recurring autoimmunity against the newly formed
insulin-producing cells. While their work gives validity to the use of lentiviral vectors for
insulin gene therapy applications, it should be noted that insulin expression was driven by the
CMV promoter and displayed no responsiveness to circulating glucose levels.
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3. Concluding remarks
Overall, insulin gene therapy provides a promising alternative to current treatments for T1DM.
Although this treatment option will inevitably lack the full sophistication of native β cells, it
would certainly improve upon current treatment options. Insulin gene therapy opens the
possibility of having a one-time treatment option that can provide long-term correction of
diabetic hyperglycemia through physiologically relevant mechanisms, like glucose-dependent
alterations in insulin transcription and translation. Further, the simplicity of the treatment
should yield reproducible results with excellent success rates and additionally help newly-
formed insulin-producing surrogate β cells evade recurring autoimmunity. However, several
hurdles must still be overcome.
In order for the treatment to be a viable option, long-term insulin expression must be driven
to avoid repeated injection. However, the viral vectors currently used to drive long-term
transgene expression, like lentivirus, are generally difficult to produce in high titer and limited
by their transduction efficiency. As a result, most successful long-term efforts in the field have
employed the CMV promoter, which can only drive strong constitutive expression of insulin.
In order to take those research efforts to the next level, weaker tissue-specific promoters must
be used that drive low basal levels of insulin expression during fasting periods and substan‐
tially upregulated insulin expression upon increases in glucose availability. To date, this has
yet to be achieved. We are currently exploring several viral vectors for their capacity to deliver
our insulin expression cassette—which has elements to drive liver-specific, glucose-responsive
insulin expression —at a therapeutic level. In so doing, we hope to produce an affordable,
long-term treatment option for patients with T1DM.
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